Medexus Pharmaceuticals Inc. (TSE:MDP) Given Consensus Rating of “Buy” by Brokerages

Medexus Pharmaceuticals Inc. (TSE:MDP) has been given a consensus rating of “Buy” by the five ratings firms that are presently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is C$5.25.

MDP has been the topic of a number of recent analyst reports. Raymond James upgraded Medexus Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from C$3.00 to C$4.00 in a research report on Wednesday, November 20th. Leede Financial set a C$8.25 price target on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a report on Monday, September 30th. Finally, Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday.

Medexus Pharmaceuticals Price Performance

Shares of TSE MDP opened at C$3.25 on Friday. Medexus Pharmaceuticals has a fifty-two week low of C$1.47 and a fifty-two week high of C$3.27. The firm has a market capitalization of C$79.72 million, a P/E ratio of 65.00 and a beta of 1.96. The company’s 50 day simple moving average is C$2.56 and its 200 day simple moving average is C$2.39.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.